

Botulinum A Toxin given intracutaneous for the treatment of focal hyperhidrosis

Dr. Hamda Al Ansari

Introduction ⁽¹⁾

Hyperhidrosis is sweating beyond what is necessary to maintain thermal regulation. Hyperhidrosis can be focal (localized) or may be generalized. Hyperhidrosis is socially embarrassing and may be disabling occupationally. Sweating is a function of the sympathetic nervous system. A sweat control center is located in the pre-optic area and anterior hypothalamus and contains neurons that are sensitive to changes in internal temperature as well as cerebral cortical events. Sweat glands are innervated by post ganglionic sympathetic cholinergic fibers. Emotionally induced sweating is usually palmoplantar and sometimes facial (forehead) while axillary sweating may result from emotional and thermal stimuli. Primary or essential axillary or Palmoplantar hyperhidrosis is estimated to affect 0.6 – 1% of population and may be inherited and is usually seen in adolescence but may begin in childhood and even infancy and does not occur while person is asleep.

The generalized hyperhidrosis may be caused by

- heat humidity and exercise
- acute febrile diseases
- chronic infections and neoplasia
- metabolic disorders which include thyrotoxicosis, diabetes mellitus, hypoglycemia, gout, pheochromocytoma, hyperpituitarism or menopause.
- Conditions like shock, syncope, intense pain, alcohol, drug withdrawal
- Neurologic causes like irritative hypothalamic lesion and Riley-Day syndrome. These are an autosomal recessive inherited disorder of the sensory and autonomic nerve function

throughout the body and is characterized by sweating specially while eating, poor growth, long episodes of vomiting, lack of response to painful stimuli, seizures, hypotonia, repeated fevers, decreased taste.

- Drugs as propranolal, physostigmine, pilocarpine, tricyclic antidepressants or venlafaxine.

Localized Hyperhidrosis

- may be primary or essential
- due to neurologic lesions
- may be gustatory (Frey’s syndrome) as with spicy food
- may be due to heat

Treatment of hyperhidrosis include:

- A- Topical medicine
 - 1- Aluminum Chloride hexahydrate 20% in anhydrous ethyl alcohol ⁽²⁾
 - 2- Glutaraldehyde 10%
 - 3- Tannic acid 2 – 5 %
 - 4- Formalin solution 5 – 20%
 - 5- Anti cholinergics
- B- Electrical treatment by iontophoresis ⁽³⁾
- C- Surgical treatment
 - 1- sympathectomy ⁽⁴⁾
 - 2- excision of axillary sweat glands
 - 3- lipo suction
- D- Systemic drug
 - 1- Treat any associated condition
 - 2- Tranquillizers as valium
 - 3- ANTICHOLINERGICS :
 - Probanthine
 - Robinul
 - Ditropan
 - Cogentin (benztropine) mesylate ⁽⁵⁾
 - 4- NSAID as indomethacin ^(6,7)
 - 5- Calcium channel blockers
 - 6- Clonidine hydrochloride (calapres) ⁽⁸⁾
 - 7- Botulinum A Toxin (Dysport) inhibits

Hyperhidrosis of	Year													
	2003		2004		2005		2006		2007		2008		Total	
	F	M	F	M	F	M	F	M	F	M	F	M	F	M
Axilla	1	1	10	6	6	8	12	4	15	21	19	8	63	48
Palm	-	1	-	1	-	2	-	-	1	-	-	3	1	7
Sole	-	-	-	-	-	1	-	-	-	1	-	-	0	2
Total	1	2	10	7	6	11	12	4	16	22	19	11	64	57
Total	3		17		17		16		38		30		121	

release of acetyl choline at post ganglionic sympathetic fibers to sweat glands and is useful to treat palmar and axillary hyperhidrosis. ^(9, 10)

Patients and Method:

In Doha, Qatar, at the department of dermatology at Hamad Medical Corporation we have been using Botox A toxin to treat localized hyperhidrosis of axillae, palms and soles.

We treated 121 adult patients, 64 females and 57 males as shown in the following table

Before treatment, cold packs are placed on palms for 30 minutes and a total dose of 120 mu (mouse unit) botulinum A diluted with 0.5 cc of 0.9% sterile saline. The drug is injected subcutaneous at six different sites, i.e. 20 mu per site. The anhidrotic or hypohidrotic response is reported up to one year but starts to weaken in four months. Its use is limited by the need of repetitive relatively painful injections, the high cost of the toxin and the report of weakness of small muscles of hands. ⁽¹⁰⁾

Botulinum A Toxin also inhibit the release of acetylcholine at neuromuscular junction and may

cause transient paresis in muscles in which it is injected ^(11, 12) and it is the treatment of choice in cranial and cervical dystonias. ^(11, 13)

Botulinum A toxin given in axillary hyperhidrosis in the dose of 200 mu given at six different sites of one axilla lead to significant reduction of sweating over a period of 13 weeks after a single treatment. ⁽¹⁴⁾ Botulinum A Toxin is a safe and effective treatment for primary axillary hyperhidrosis and produces high levels of patient satisfaction ⁽¹⁵⁾ and the treatment is easily administered. Botulinum toxin is an effective safe and long lasting alternative therapeutic modality for treatment of severe palmar hyperhidrosis. ⁽¹⁶⁾

Conclusion

Botulinum Toxin is a polypeptide that is injected at the junction of the dermis and subcutaneous tissue where sweat glands are located and to minimize pain, it is advisable to do median and ulnar nerve block for palms and medial ankle and Tibial nerve block for plantar hyperhidrosis using 1 or 2% lidocaine. ⁽¹⁷⁾ The intracutaneous botulinum toxin is preferred to any conservative or surgical treatment and is the treatment of choice in localized hyperhidrosis. ⁽¹⁸⁾

References:

- 1- Lewis O Stolman: *Treatment of Hyperhidrosis. Dermatologic Clinics, 1998; 16(4): 863-67.*
- 2- Shelley WB; Laskas JJ; Satonove A: *Effect of topical agents on Plantar sweating. Archives of Dermatology and Syphilology 1954; 69: 713 – 16.*
- 3- Stolman LP: *The treatment of palmar hyperhidrosis by iontophoresis. Arch. Derm 1987; 123: 893-96.*
- 4- Moran KT; Brady MP: *Surgical management of primary hyperhidrosis. Br. J. Surg 1991; 78: 279 – 83.*
- 5- Garber A; Gregory R: *Benzotropine in the treatment of venlafaxine – induced sweating. J. Clin. Psychiatry 1997; 58: 4176 – 177.*
- 6- Goldyne ME: *Indomethacin and hyperhidrosis. J. Am. Acad Dermatol 1983; 7: 801.*
- 7- Tkach JR: *Indomethacin treatment of generalized hyperhidrosis. J Am Acad Dermatol 1982; 6: 545.*
- 8- Feder R: *Clonidine treatment of excessive sweating. J. Clin, Psychiatry 1995; 56 (1): 35.*
- 9- Bushara KO; Park DM; Jones JC; et al: *Botulinum toxin a possible new treatment for axillary hyperhidrosis. Clin. Exp. Dermatol 1996; 21: 276 – 78.*
- 10- Schnider P; Binder M; Auff E; et al: *Double blind trial of Botulinum A Toxin for treatment of focal hyperhidrosis of palms. Br. J. Dermatol 1997; 136: 548 – 52.*
- 11- Tsui JKC; Eisen A; Stoessl AJ; et al: *Double blind study of Botulinum toxin in spasmodic torticollis Lancet 1986; ii: 245-7.*
- 12- Poewe W; Schelosky L; Kleedorfer B; et al: *Treatment of Spasmodic torticollis with local injection of botulinum toxin. J Neural 1992; 239: 21-5.*
- 13- Grandas F; Elston J; Quinn N; et al: *Blepharospasm: a review of 264 patients. J. Neural Neurosurg Psychiatry 1988; 51: 767 – 72.*
- 14- Schneider P; Binder M; Kittler H; et al: *A randomized double-blind, placebo controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br. J. Dermatol 1999; 140: 677 – 80.*
- 15- Naumann M; Lowe NJ: *On behalf of the hyperhidrosis clinical study group: Botulinum toxin types A in treatment of bilateral primary axillary hyperhidrosis: randomized, parallel groups, double blind placebo controlled trial. B. M. J 2001; 323: 596-99.*
- 16- Shelley WB; Talanin NY; Shelley ED: *Botulinum Toxin therapy for palmar hyperhidrosis. J. Am Acad Dermatol 1998; 38: 227-9.*
- 17- Mayumi Fujita; Teresa Mann; Orville Mann; et al: *Surgical Pearls: Use of nerve blocks for botulinum toxin treatment of palmar plantar hyperhidrosis. J Am Acad Dermatol. 2001; 45: 587-9.*
- 18- Nauman M; Hofmann U; Bergmann I; et al: *Focal hyperhidrosis. Effective treatment with intracutaneous Botulinum Toxin. Arch Dermatol 1998; 134: 301 – 304.*